<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1993">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338698</url>
  </required_header>
  <id_info>
    <org_study_id>12(06)/2016-Coord</org_study_id>
    <nct_id>NCT04338698</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shehnoor Azhar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Health Sciences Lahore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr
      thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin
      (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and
      in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat
      and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary
      outcomes).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A scientific taskforce notified by the Ministry of Science and Technology of the Government
      of Pakistan will oversee a comprehensive cohort study. Within this cohort, a multicenter,
      adaptive, randomized controlled trial will evaluate, among eligible SARS-Cov-2 (COVID-19)
      infected patients receiving standard supportive care who consent to randomization following a
      new diagnosis in Pakistan, if Hydroxychloroquine Phosphate/Sulfate alone (control
      intervention) vs a series of alternatives (comparator interventions) including Oseltamivir
      and Azithromycin alone and in combination with Hydroxychloroquine Phosphate/Sulfate is
      effective in clearing the coronavirus and improving the clinical course of the disease. Those
      not consenting to randomization will be followed up for outcomes of SARS-Cov-2 infection with
      supportive care only. Findings of this study are expected to inform clinical care and public
      health protocols and policies for management of SARS-Cov-2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adaptive design (sample size given below is indicative)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory Result</measure>
    <time_frame>Day 07 on follow-up</time_frame>
    <description>The laboratory-based primary outcome will be turning test negative for COVID-19 on RT-qPCR calculated as viral load of &lt; 150 i.u</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>Day 07 on follow-up</time_frame>
    <description>The clinical primary outcome will be improvement of two points on a seven-category ordinal scale shown below:
Not hospitalized, able to resume normal activities
Not hospitalized, but unable to resume normal activities
Hospitalization, not requiring supplemental oxygen
Hospitalization, requiring supplemental oxygen
Hospitalization, requiring noninvasive mechanical ventilation
Hospitalization, requiring invasive mechanical ventilation
Death</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Control Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine + Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine + Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir + Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxyquinine + Oseltamivir + Azithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Cohort</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-consenting to randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine Phosphate/Sulfate (200 mg orally thrice a day for 5 days)</description>
    <arm_group_label>Comparator 3</arm_group_label>
    <arm_group_label>Comparator 4</arm_group_label>
    <arm_group_label>Comparator 6</arm_group_label>
    <arm_group_label>Control Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oseltamivir (75 mg orally twice a day for 5 days)</description>
    <arm_group_label>Comparator 2</arm_group_label>
    <arm_group_label>Comparator 4</arm_group_label>
    <arm_group_label>Comparator 5</arm_group_label>
    <arm_group_label>Comparator 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)</description>
    <arm_group_label>Comparator 1</arm_group_label>
    <arm_group_label>Comparator 3</arm_group_label>
    <arm_group_label>Comparator 5</arm_group_label>
    <arm_group_label>Comparator 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result

          2. Either gender

          3. Symptomatic for example fever, dry Cough, difficulty to breathe

        Exclusion Criteria:

          1. Confirmed absence of SARS-CoV-2 (COVID-19) infection by a negative test result

          2. Have chronic conditions such as heart disease, liver and kidney failure

          3. Pregnant or currently lactating

          4. Immunocompromise and/or systemic disease(s)

          5. On other antiviral drugs

          6. History of allergy to any of the drugs to be administered in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javed Akram, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Health Sciences Lahore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shehnoor Azhar, MPH</last_name>
    <phone>+92 321 4090221</phone>
    <email>shehnoor.azhar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faislabad Medical University</name>
      <address>
        <city>Faisal훮bad</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanif Nagra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gujranwala Medical College</name>
      <address>
        <city>Gujr훮nw훮la</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maroof Aziz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nawaz Sharif Medical College</name>
      <address>
        <city>Gujr훮t</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szabmu-Pims</name>
      <address>
        <city>Islamabad</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanweer Khaliq</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akram Medical Complex</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shehla Javed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fatima Jinnah Medical University</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamir Zaman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Edward Medical University-Mayo Hospital</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid M Gondal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahore General Hospital</name>
      <address>
        <city>Lahore</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farah Sadiq</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khyber Teaching Hospital</name>
      <address>
        <city>Peshawar</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saadia Ashraf</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rawalpindi Medical University</name>
      <address>
        <city>Rawalpindi</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Umar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sargodha Medical College</name>
      <address>
        <city>Sargodha</city>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saifullah Goraya</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Health Sciences Lahore</investigator_affiliation>
    <investigator_full_name>Shehnoor Azhar</investigator_full_name>
    <investigator_title>Study Coordinator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

